Introduction
============

Endovascular treatment via stent implantation or percutaneous transluminal coronary angioplasty (PTCA) is the preferred method for lower extremity arterial occlusive diseases ([@b1-mmr-13-06-4959],[@b2-mmr-13-06-4959]). PTCA has been the predominant method of coronary revascularization; however, the incidence of restenosis is 30--50%, which limits its use and increases the use of drug-eluting stents ([@b3-mmr-13-06-4959]). Results from treating superficial femoral artery disease by implantation of nitinol stents were superior to those treated with balloon angioplasty with optional secondary stenting, with 6-month restenosis in 24% of the patients with stents and in 43% of patients receiving angioplasty ([@b2-mmr-13-06-4959]). At 12 months, the patency rates are 37 and 63%, respectively, with 32% of angioplasty patients receiving secondary stenting ([@b4-mmr-13-06-4959]). Asymptomatic in-stent restenosis (ISR) and neointimal proliferation are observed in patients with stent implantation as early as one year subsequent to treatment ([@b1-mmr-13-06-4959]). ISR appears to be the result of a number of factors and investigators have presented multiple hypotheses, including early-stage vascular recoil, platelet aggregation and thrombus formation, infiltration of local inflammatory cells (T lymphocytes, neutrophils and monocyte-macrophage cells) into the damaged blood vessels, neointimal hyperplasia and extracellular matrix formation, and remodeling of blood vessel walls ([@b3-mmr-13-06-4959],[@b5-mmr-13-06-4959]--[@b7-mmr-13-06-4959]). However, a definite cause-effect association remains to be determined. Although drug-eluting stents are used consistently to effectively reduce ISR ([@b8-mmr-13-06-4959],[@b9-mmr-13-06-4959]), restenosis remains a critical clinical issue for vascular surgeons.

The Chinese herb, *Tripterygium wilfordii* Hook F (TWHF), has long been reported to exhibit anti-inflammatory and immunosuppressive effects ([@b10-mmr-13-06-4959],[@b11-mmr-13-06-4959]), which are largely attributed to the diterpenoid triepoxides, triptolide and tripdiolide (the predominant components of the herb) ([@b12-mmr-13-06-4959]). The purified extract triptolide has been widely used in Chinese traditional medicine to treat inflammatory and autoimmune diseases, including rheumatoid arthritis, lupus erythematosis, nephritis and asthma. Triptolide combined with cyclosporin A (CsA) induced immune tolerance in a rat renal allograft rejection model ([@b13-mmr-13-06-4959]). Triptolide extracted from TWHF has also been demonstrated to exhibit antiproliferative and pro-apoptotic functions in a number of tumor cell lines ([@b14-mmr-13-06-4959],[@b15-mmr-13-06-4959]). Recently, it was investigated for its effects on ISR inhibition of rat vascular smooth muscle cell (VSMC) proliferation and cell cycle progression, demonstrating an inhibitory effect on the VSMC cell cycle, inactivation of the mitogen-activated protein kinase signaling pathway and modulation of cell cycle proteins, cyclin-dependent kinase inhibitor 1 (p21^cip1^) and retinoblastoma protein ([@b16-mmr-13-06-4959]). It was also demonstrated that triptolide-eluting stents attenuated neo-intimal formation following stent implantation in rabbit blood vessels ([@b16-mmr-13-06-4959]).

Tripterygium glycosides that are used commercially for their anti-inflammatory and immunosuppressive effects are extracted from TWHF by column chromatography. Although its use is considered effective in the treatment of inflammatory and autoimmune diseases, it is also associated with toxic effects to the liver and kidneys. In a recent study, the cytotoxic effects and anti-inflammatory activity of the three components of tripterygium glycosides were evaluated in an effort to reduce toxicity ([@b17-mmr-13-06-4959]). Toxicity was thus reduced by changing the extraction method from column chromatography to sodium carbonate extraction, which removed the acidic compounds, and enriched the epoxyditerpenoids and alkaloids in the resulting extract. Animal experiments have demonstrated that the therapeutic index of the extract on rat tissue (murine macrophage and mesangial cells) was markedly higher than that of tripterygium glycosides, and the cytotoxicity in human liver cells was notably lower ([@b17-mmr-13-06-4959]). The toxic effects were thereby reduced and the novel tripterygium glycosides preparation demonstrated effective biological activity and safety in human patients.

VSMC proliferation is a key factor in the mechanism of restenosis; thus, inhibiting this process is hypothesized to exert a beneficial therapeutic effect on ISR. The present study hypothesized that if tripterygium glycosides inhibit cell proliferation, cell cycle progression and protein expression in an animal model of stent implantation, differences may also be observed in outcomes between patients receiving tripterygium glycosides and bare-stents following endovascular treatment of lower-extremity artery disease. With the exception of the recent study by Tao *et al* ([@b16-mmr-13-06-4959]), no published studies have focused on the effect of tripterygium glycosides on restenosis. Thus, the present two-part experimental and clinical study aimed to investigate the effects of oral administration of tripterygium glycosides on ISR.

Materials and methods
=====================

Two-part study
--------------

The current two-part prospective study included a basic experimental study and a follow-up clinical study. The experimental study was performed between January 2010 and March 2010 and the clinical study was conducted between May 2010 and January 2014 at the Department of Vascular Surgery, The Second Hospital of Baoding City (Baoding, China). The Internal Review Board and the Institutional Animal Care and Use Committee of the hospital reviewed and approved the study protocol. Animals were cared for according to the Regulations for the Administration of Affairs Concerning Experimental Animals (<http://old.biovip.com/content/20050417/11036.htm>). All human subjects in the clinical study provided signed informed consent to participate.

Experimental study
------------------

### Experimental procedure

Twenty-four healthy male New Zealand white rabbits (age, 2--3 months; weight, 2.0±0.30 kg) were purchased from the Experimental Animal Center of Hebei Medical University (Shijiazhuang, China). The rabbits were maintained at 20--23°C, with 40--60% humidity and a 12-h light/dark cycle. They were fed a normal diet for one week and then received implantation of an endovascular stent (ev3 bare-metal coronary artery stents with diameter and lengths of 3.0 and 10--18 mm, respectively; Lepu Medical Technology Co., Ltd., Beijing, China). Following successful implantation, the rabbits were randomly divided into four groups: Bare stent group; CsA (Novartis International AG, Basel, Switzerland) group, 0.5 mg/kg tripterygium glycosides (Shanghai Fudan Forward S&T Co., Ltd., Shanghai, China) group; and 1 mg/kg tripterygium glycosides group. All agents were administered 1 day after balloon angioplasty injury via intramuscular injection to the iliac arteries and were continued for 28 days. All rabbits were sacrificed at day 29 by anesthesia with 10% potassium chloride (injected into rabbit ear vein).

### Therapeutic agents

Tripterygium glycosides in tablet form were isolated and purified from tripterygium, as the components triptolide and tripdiolide have been indicated for use as anti-inflammatory and immunosuppressive compounds, as previously described ([@b10-mmr-13-06-4959]). Following endovascular stent implantation, 7.14 mg/kg/day CsA was administered by intramuscular injection for the first 5 days, 1.02 mg/kg/day CsA was administered from days 6--14, and 0.678 mg/kg/day CsA was administered from days 15--28. Animals were administered 3.0 g finely ground tripterygium glycosides powder mixed evenly with 0.5% sodium carboxymethyl cellulose (Sigma-Aldrich), and suspended in 100 ml solution and 3.0 and 1.5% solutions were prepared in turn. Dosage was determined according to the equivalent dosage for human beings; low and high doses of the therapeutic agents for the rabbits were 3 times (1.5 mg/kg/day) and 6 times (3.0 mg/kg/day) the daily doses for human beings due to their faster metabolic rate, and prepared for intragastric administration.

### Rabbit iliac artery angiography

A Siemens angiography system was applied (Siemens AG, Munich, Germany), measuring intima-media thickness at a frequency range of 4--9 Hz and observing for morphologic deformities, including plaque, stenosis and occlusion. Inner stenosis was calculated using the Siemens angiography system. Each rabbit was fixed and the left femoral artery was exposed and isolated. Injection of 5--10 ml iohexol (contrast agent; Sigma-Aldrich) from a 100 ml solution containing 30 g iodine was administered to display the left iliac artery and the right iliac artery containing the endovascular stent and the images were captured and saved using the Siemens angiography system.

### Material collection

Rabbits were sacrificed at the end of the experiment (day 29) following anesthesia. The rabbit iliac artery containing the stent was aseptically removed. The artery included adjacent proximal and distal vessel segments 5 mm in length, which were divided into two parts. One part was fixed with 4% paraformaldehyde (Sigma-Aldrich) for hematoxylin and eosin staining (Sigma-Aldrich) and immunohistochemical staining. The second part was fixed with 3% glutaraldehyde (Sigma-Aldrich) for examination with an S-3400 N scanning electron microscope (Hitachi, Tokyo, Japan).

### Immunohistochemistry (IHC) of proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), cyclin-dependent kinase 2 (CDK2) and p21^Cip1^

The rabbit iliac artery tissue sections were stained using Histostain-Plus kits (Zhongshan Biological Products Co., Ltd., Beijing, China) according to the manufacturer\'s protocols. The sections were subsequently incubated with primary antibody at 4°C overnight, and then with secondary antibody at room temperature for 15 min. Primary antibodies included: 0.1 ml (100 *µ*g/ml) of monoclonal mouse anti-PCNA (1:5,000; Wuhan Boster Biological Technology, Inc., Wuhan, China; cat. no. 610664), 0.1 ml (100 *µ*g/ml) of polyclonal rabbit anti-VEGF (1:200; Abcam, Cambridge, MA, USA; cat. no. ab46160), 0.1 ml (100 *µ*g/ml) of polyclonal rabbit anti-cyclin-dependent kinase 2 (CDK2; 1:200; Wuhan Boster Biological Technology, Inc.; cat. no. 8233343), and 0.1 ml (100 *µ*g/ml) of monoclonal mouse anti-cell-cycle regulatory protein (p21^Cip1^; 1:250; Wuhan Boster Biological Technology, Inc.; cat. no. 554262). The secondary antibodies included biotin-labeled goat anti-rabbit IgG (SP-9001) and biotin-labeled goat anti-mouse IgG (SP-9002). Following washing with phosphate-buffered saline, the sections were incubated with horseradish peroxidase-labeled streptavidin at room temperature for 15 min. 3,3-Diaminobenzidine (Sigma-Aldrich) was applied followed by hematoxylin counterstaining. Sections were examined with a BX60 microscope (Olympus Corporation, Tokyo, Japan).

Clinical study: Patients and methods
------------------------------------

### Study design

This was a prospective case-control clinical study evaluating the effects of tripterygium glycosides on restenosis in patients undergoing balloon angioplasty and stent implantation. As tripterygium glycosides have been used in clinical practice in China prior to the present study, it was not registered as a clinical trial. This was in accordance with a previous systematic review of Chinese herbal medicines used for preventing in-stent coronary stenosis following percutaneous coronary intervention ([@b18-mmr-13-06-4959]).

### Subjects

A total of 120 patients who had undergone treatment for cardiovascular disease were included. Diagnoses were made according to guidelines of the Chinese Association of Integrative Medicine ([@b19-mmr-13-06-4959]). Inclusion criteria were: i) Symptoms including leg coldness, numbness and pain, and/or intermittent claudication or physical signs, such as low lower-extremity skin temperature, decrease or absence of dorsalis pedis artery pulse; ii) presence of arterial plaque formation or occlusion in the lower extremity proven by arterial Doppler exam of the lower extremities; iii) presence of stenosis or occlusion in the superficial femoral artery confirmed by angiography; and iv) patients who were in the second stage (dystrophy period) or third stage (necrosis stage) of ISR. Based on the random number table, patients were divided into a control group of 40 patients (42 limbs), a low-dose tripterygium glycosides group of 40 patients (45 limbs) and a high-dose tripterygium glycosides group of 40 patients (43 limbs) at a ratio of 1:1:1. Patients with the following were excluded from the study: i) Associated severe renal dysfunction (indicated by creatinine clearance rate \<30 ml/min), liver dysfunction (Child-Pugh classification grade B or C), heart failure (New York Heart Association functional classification grade III or IV); ii) a variety of acute complications of diabetes or stress states, including serious diseases and critical conditions; iii) associated malignant diseases and active bleeding disorders; iv) taking therapeutic agents affecting evaluation of the present therapeutic agent efficacy, including other vasodilators and therapeutic agents affecting microcirculation (including pentoxifylline, hormones, clofibrate, pyridolcarbates and nicotinic acid); v) occlusive thrombotic vasculitis and aorto-arteritis; vi) adverse reactions, such as a marked decrease in the number of white blood cells or liver and kidney damage during tripterygium glycosides treatment, which required therapeutic agent withdrawal, and who failed to recover after two weeks.

### Treatment protocol

All 120 patients underwent endovascular treatment (balloon angioplasty or stent implantation). Bare metal stents (ev3 bare-metal stent) were implanted in the coronary artery of all patients. The range of endovascular stent diameters was 6.0--7.0 mm, and the range of endovascular stent length was 6--12 mm. Subcutaneous injection of low molecular weight heparin (5,000 U/8 h) was conducted for 5 days. Clopidogrel bisulfate (75 mg/day; Sigma-Aldrich) was administered for 3 months. The low-dose group received 0.5 mg/kg/day tripterygium glycosides in tablet form administered orally twice a day for 60 days (with routine blood tests performed once every two weeks and liver and kidney function tests once every month). The high-dose group received 1 mg/kg/day tripterygium glycosides in tablet form administered orally twice a day for 60 days (with routine blood tests performed once every two weeks and liver and kidney function tests once every month).

### Main outcome measures

Prior to administration of therapeutic agents and at 4 and 12 weeks following treatment, fasting venous blood samples were drawn in the morning. Interleukin (IL)-10, IL-18 and C-reactive protein (CRP) levels were measured by enzyme-linked immunosorbent assay (R&D Systems, Inc., Minneapolis, MN, USA), and the intima-media thickness and patency rate of the lower extremity arteries were detected by Doppler ultrasound (ACUSON S2000, Siemens AG) and built-in software.

### Statistical analysis

Differences in vessel diameter (VD), post-operative diameter, measurements of lumen/neointimal (NI)/medial (M) area, ratio of NI-to-M, protein expression levels amongst the four groups of rabbits, as well as the baseline characteristics, protein expression levels, number of stents without marked intimal hyperplasia and ankle-brachial index (ABI) amongst the 3 groups of patients were compared using Fisher\'s exact or χ^2^ tests for categorical variables and one-way analysis of variance (ANOVA) for continuous variables. Following the ANOVA, post hoc analysis was conducted with multiple comparisons, including the significance of pair-wise differences tested using Tukey\'s test for balanced design with equal variance, Bonferroni\'s correction for unbalanced design with equal variance, or Dunnet\'s T3 test for unequal variance amongst groups. Tukey\'s test and Dunnet\'s T3 test consider familywise error. Group effect, time effect and the interaction between these two parameters were examined by generalized estimation equation. All tests were 2-sided and P\<0.05 was considered to indicate a statistically significant difference. All analyses were conducted using SPSS software package version 15.0 (SPSS, Inc., Chicago, IL, USA).

Results
=======

High-dose tripterygium glycosides improve the post-operative vessel diameter (POVD) and ratio of NI to M
--------------------------------------------------------------------------------------------------------

Following administration of the therapeutic agents to the 4 groups of rabbits as described above, angiography of the iliac artery stenosis was conducted at 28 days ([Fig. 1](#f1-mmr-13-06-4959){ref-type="fig"}). The angiography prior to implantation is also demonstrated ([Fig. 1A](#f1-mmr-13-06-4959){ref-type="fig"}). The baseline VD, POVD, lumenal area, NI, M and ratio of NI-to-M of rabbits in the 4 groups are listed in [Table I](#tI-mmr-13-06-4959){ref-type="table"}. The baseline VD and POVD were similar in all groups. However, 28 days after administration of therapeutic agents, the POVD values in all rabbits in the CsA and tripterygium glycosides groups were significantly increased compared with those of the control group. Although the POVD of the low-dose group was significantly smaller than that of the CsA group at 28 days, the high-dose and the CsA groups had comparable POVD. The greatest reductions and percentage changes in POVD were observed in the control group, and the lowest changes were observed in the CsA and high dose tripterygium glycosides groups. Thus, the high-dose of tripterygium glycosides exerted a similar effect on POVD at day 28, when POVD loss and percentage change of the POVD was compared with CsA. Excluding the lumenal area, the NI, M and the ratio of NI-to-M in the CsA and tripterygium glycosides groups were significantly smaller than those of the control group. The lumenal area in the control group was significantly smaller than that in the other groups. Although smaller lumenal area and greater NI area, as well as the ratio of NI-to-M were observed in the low-dose tripterygium glycosides group when compared with the CsA, the CsA group and the high-dose group had comparable values of these variables. The lowest ratio of NI-to-M was observed in the CsA group, and the largest ratio was observed in the control group.

Cells treated with high-dose tripterygium glycosides exhibit almost normal endothelial cell alignment
-----------------------------------------------------------------------------------------------------

Scanning electron microscopy observation of the rabbit iliac artery, which was conducted 28 days after administration of therapeutic agents, is presented in [Fig. 2](#f2-mmr-13-06-4959){ref-type="fig"}. In the bare stent control group, the alignment of endothelial cells on the intimal surface of new blood vessels was relatively disordered, the sizes and morphologies of cells were different, the nuclei were irregular, and the intercellular space was relatively large. In the low-dose tripterygium glycosides group, the alignment of endothelial cells on the intimal surface was relatively regular compared with the bare stent control group, and the size, morphology, nuclear morphology and intercellular space were markedly improved than those of the bare stent group. In the CsA group, the alignment of endothelial cells on the intimal surface of new blood vessels was relatively regular and tight, the direction of alignment was close to the direction of blood flow, the inter-cellular space was relatively small, the morphology and size of endothelial cells were relatively identical, and the nuclei were relatively regular. The intercellular space and endothelial cells were almost normal. Numerous scattered microvilli were observed on cell surfaces. In the high-dose tripterygium glycosides group, the alignment of endothelial cells on the intimal surface of new blood vessels, the size, morphology, nuclear morphology and intercellular space were similar to those in the CsA group. However, the microvilli were distributed along the outline of cells and the distribution was more even with increased number, which suggests that the function of these cells was closer to that of the normal endothelial cells.

Tripterygium glycosides downregulate the expression of PCNA, VEFG and CDK2 and upregulated expression of p21^Cip1^
------------------------------------------------------------------------------------------------------------------

Protein expression of PCNA, VEFG, CDK2 and p21^Cip1^ are listed in [Table II](#tII-mmr-13-06-4959){ref-type="table"}. Compared with rabbits in the vehicle control group, CsA and tripterygium glycosides at high and low doses significantly downregulated protein expression of PCNA, VEFG and CDK2, however, they significantly upregulated p21^Cip1^ protein expression (all P\<0.001). Notably, the high-dose group and CsA group had comparable levels of all four proteins. The representative IHC images are presented in [Figs 3](#f3-mmr-13-06-4959){ref-type="fig"}[](#f4-mmr-13-06-4959){ref-type="fig"}[](#f5-mmr-13-06-4959){ref-type="fig"}--[6](#f6-mmr-13-06-4959){ref-type="fig"}.

Administration of tripterygium glycosides results in adverse reactions in five patients
---------------------------------------------------------------------------------------

Five patients in the treatment group had adverse reactions that were resolved following therapeutic agent withdrawal, they were excluded from the final analysis of the present study. In the low-dose tripterygium group, one patient had nausea and vomiting, and another had an abnormal blood cell response (leukopenia, erythroblastopenia and granulocytopenia). In the high-dose group, one patient had nausea and vomiting, one had an abnormal blood cell response (leukopenia, erythroblastopenia and granulocytopenia), and a third patient had low blood pressure and an accelerated heart rate.

No significant difference is observed in baseline characteristics of the patients
---------------------------------------------------------------------------------

Baseline characteristics of all patients are presented in [Table III](#tIII-mmr-13-06-4959){ref-type="table"}. Among the three groups of patients, there were no significant differences in age, gender distribution, course of disease, and prevalence of hypertension, cardiovascular disease, cerebrovascular disease, intermittent claudication, hyperlipidemia, leg pain, leg ulcer, leg coldness, and Trans-Atlantic Inter-Society Consensus (TASC) stage.

IL-10 and IL-18 are significantly reduced following treatment with tripterygium glycosides
------------------------------------------------------------------------------------------

The three groups of patients had comparable levels of IL-10, IL-18, CRP and intima-media thickness when measured at the baseline ([Table IV](#tIV-mmr-13-06-4959){ref-type="table"}). One month after the surgery, IL-10 and IL-18 levels were increased, and then decreased in the 2nd month in all groups. Tripterygium glycosides at the two doses significantly reduced IL-10 and IL-18 levels compared with those in the control group. Although the CRP level and intima-media thickness of the control group were slightly elevated following surgery, no significant differences were observed in these parameters among the three patient groups.

Six months following the surgery, the stent patency rate in patients with bare stents was lower compared with that in patients receiving tripterygium glycosides
----------------------------------------------------------------------------------------------------------------------------------------------------------------

At 6 months, the stent patency rates were 67.5% in the control group, 90.9% in the low-dose group and 93.8% in the high-dose group (P=0.004); at 12 months, the rates for each group were 62.5% for the control group, 84.8% for the low-dose group and 90.6% for the high-dose group (P=0.009). Patients administered tripterygium glycosides had higher ankle-brachial index than those not administered tripterygium glycosides, 0.47 vs. 0.73 in the low-dose group and 0.79 in the high-dose group at 6 months; 0.49 vs. 0.70 in the low-dose group and 0.75 in the high-dose group at 12 months (P\<0.001 for the two doses; [Table V](#tV-mmr-13-06-4959){ref-type="table"}).

Discussion
==========

Results of the present experimental study demonstrated that CsA and tripterygium glycosides inhibited DNA synthesis in cellular proliferation, inhibited regulation of chromosomal DNA replication in S phase, suppressed aggravation of immune rejection and enhancement of inflammatory cell infiltration, and decreased cell cycle progression, inducing Gl, G2 and S-phase arrest. In addition, the alignment of endothelial cells on the intimal surface in the tripterygium glycosides low and high dose groups was more regular than that in the bare stent group, and the size, morphology, nuclear morphology and cell patency were markedly improved in the tripterygium glycosides groups compared with those in the bare stent control group. The present study hypothesized that CsA and tripterygium glycosides may inhibit and delay the occurrence of ISR. Results of the present study demonstrated that tripterygium glycosides inhibited the expression of PCNA, CDK2 and VEGF proteins and enhanced p21^Cip1^ protein expression in VSMCs. These effects on important cell-cycle proteins were more marked in the high-dose tripterygium glycosides group, suggesting that the administration of tripterygium glycosides inhibited ISR formation. Results of the present experimental study also indicated that immune rejection was involved in ISR formation, which may be an important mechanism provoking ISR.

Results from the clinical observation of 120 patients in the current study demonstrated that the patency rate of the diseased blood vessels was reduced to 60% at 12 months following endovascular treatment in the control group, while the patency rate was 85% in the tripterygium glycosides group. In addition, the therapeutic outcomes of high-dose tripterygium glycosides administration were improved compared with those of the low-dose tripterygium glycosides. Plasma IL-10 and IL-18 levels in the tripterygium glycosides group were significantly lower than those in the control group, indicating notable anti-inflammatory effects. The safety of administration of tripterygium glycosides was indicated by the limited number of mild adverse reactions (5 patients with digestive, blood cell or cardiologic disturbances), which resolved following therapeutic agent withdrawal.

Restenosis or occlusion following endovascular treatment is a critical clinical problem for vascular surgeons, and intimal hyperplasia is a characteristic pathological feature of the restenosis following endovascular treatment ([@b20-mmr-13-06-4959]). Hyperproliferation of VSMCs and their migration to the intima within the diseased blood vessels are important pathological bases of neointimal hyperplasia and the key pathological features of numerous factors inducing restenosis following recanalization ([@b21-mmr-13-06-4959]). Currently, the use of drug-eluting stents is reducing restenosis. Tao *et al* ([@b16-mmr-13-06-4959]) coated stents with a mixture of synthetic polymers blended with triptolide and demonstrated that the triptolide-eluting stents inhibited neointimal formation in a rabbit iliac artery model. As in the current study, the inhibition of VSCM proliferation by extracts of TWHF (triptolide and tripterygium glycosides) is an important indicator of the regulatory mechanism underlying vascular wall tension, which is crucial in preventing restenosis. Another similarity between the results of the present study and those of Tao *et al* ([@b16-mmr-13-06-4959]) is the upregulation of p21^Cip1^, suggesting that the antiproliferative effect of TWHF extracts on VSCM may be associated with p21^Cip1^ expression.

Statins have also been employed to inhibit neointima hyperplasia and vascular inflammation. However, a recent comparison of an atorvastatin-eluting stent vs. a paclitaxel-eluting stent in a rabbit iliac artery overstretch restenosis model did not demonstrate significant differences in neointimal hyperplasia, but did demonstrate more effective arterial healing within arteries of rabbits receiving atorvastatin ([@b22-mmr-13-06-4959]). In another study comparing long-term clinical and angiographic outcomes of patients with severe calcified lesions following administration of one of two widely used drug-eluting stents, the paclitaxel-eluting stent or the sirolimus-eluting stent, no significant differences were demonstrated between the two therapeutic agents (restenosis rates were 21.1% for sirolimus and 17.5% for paclitaxel) ([@b23-mmr-13-06-4959]). Direct drug-eluting stenting without pre-dilation also did not reduce restenosis compared with conventional or provisional stenting in patients with percutaneous coronary intervention ([@b24-mmr-13-06-4959]).

Tripterygium glycosides were previously reported to exert strong anti-inflammatory and immunosuppressive effects ([@b10-mmr-13-06-4959]). Tripterygium glycosides tablets have been demonstrated to reduce the inflammatory response in rat lung tissue ([@b25-mmr-13-06-4959]), and the mechanism in the rat model of arthritis was hypothesized to be associated with upregulating IL-10 expression and downregulating tumor necrosis factor (TNF)-α levels ([@b26-mmr-13-06-4959]). The anti-inflammatory properties include antagonizing and inhibiting the release of inflammatory mediators and the degree of response. The immunosuppressive properties include inhibition of T-cell function, delayed-type hypersensitivity, IL-1 secretion and antigen-stimulated cell division and reproduction. Results from the present study have indicated the involvement of immune rejection as a factor in ISR formation, this suggests that the immunosuppressive effects of tripterygium glycosides may effectively inhibit ISR.

Limitations of the present study include that serum cytokines in rabbits were not quantified in the experimental study. In addition, although IL-10 and IL-18 were quantified in patients in the clinical study, the typical pro- and anti-inflammatory cytokines, including IL-1β, IL-6, IL-4 and TNF-α, were not measured. The patients\' vessel diameter and percent stenosis were also not measured in the clinical trial, which may improve the analysis of future results. These measures remain to be completed in future investigation. Further investigation into the antiproliferative effects of tripterygium glycosides is particularly required to confirm and expand the results of the present study, and to continue to investigate the inhibition of ISR formation and associated mechanisms. Long-term follow up of clinical outcomes is also required.

In conclusion, results of the present experimental and clinical studies have demonstrated that the anti-inflammatory and immunosuppressive effects of tripterygium glycosides may inhibit in-stent restenosis formation following endovascular treatment of lower-extremity artery disease. Thus, tripterygium glycosides may be a candidate for preventing stent restenosis and/or reducing restenosis rates currently observed in clinical practice.

![Angiography of iliac artery stenosis was conducted (A) prior to implantation or (B--E) 28 days later. (B) Control group, (C) cyclosporin A group, (D) low-dose and (E) high-dose tripterygium glycosides groups.](MMR-13-06-4959-g00){#f1-mmr-13-06-4959}

![Scanning electron microscope observation of the rabbit iliac artery was conducted 28 days after administration of the therapeutic agents (magnification, ×2000). (A) Control group demonstrating disordered alignment of endothelial cells, (B) CsA group demonstrating relatively regular alignment close to the direction of blood flow, (C) low-dose and (D) high-dose tripterygium glycosides groups demonstrating similar cell alignment to the CsA group with increased microvilli. CsA, cyclosporin A.](MMR-13-06-4959-g01){#f2-mmr-13-06-4959}

![Rabbit iliac arteries. The representative immunohistochemistry images of proliferating cell nuclear antigen (magnification, ×200). (A) Control group, (B) cyclosporin A group, and (C) low-dose and (D) high-dose tripterygium glycosides groups.](MMR-13-06-4959-g02){#f3-mmr-13-06-4959}

![Rabbit iliac arteries. The representative immunohistochemistry images of vascular endothelial growth factor (magnification, ×200). (A) Control group, (B) cyclosporin A group, and (C) low-dose and (D) high-dose tripterygium glycosides groups.](MMR-13-06-4959-g03){#f4-mmr-13-06-4959}

![Rabbit iliac arteries. The representative immunohistochemistry images of cyclin-dependent kinase 2 (magnification, ×200). (A) Control group, (B) cyclosporin A group, and (C) low-dose and (D) high-dose tripterygium glycosides groups.](MMR-13-06-4959-g04){#f5-mmr-13-06-4959}

![Rabbit iliac arteries. The representative immunohistochemistry images of cyclin-dependent kinase 1 (magnification, ×200). (A) Control group, (B) cyclosporin A group, and (C) low-dose and (D) high-dose tripterygium glycosides groups.](MMR-13-06-4959-g05){#f6-mmr-13-06-4959}

###### 

Iliac arteriostenosis in 24 rabbits.

  Parameter                                 Vehicle control(n=6)   CsA (n=6)                                                  Low-dose tripterygium glycosides (n=6)                                                                    High-dose tripterygium glycosides (n=6)                                                                   P-value
  ----------------------------------------- ---------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- -----------------------------------------------------------
  VD (mm)                                   2.46±0.03              2.48±0.03                                                  2.47±0.05                                                                                                 2.48±0.02                                                                                                 0.632
  POVD (mm)                                 2.87±0.05              2.90±0.03                                                  2.88±0.03                                                                                                 2.89±0.03                                                                                                 0.555
  POVD/VD                                   1.17±0.01              1.17±0.02                                                  1.17±0.02                                                                                                 1.17±0.02                                                                                                 0.996
  POVD at D28 (mm)                          1.21±0.03              2.18±0.04[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}    1.97±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn3-mmr-13-06-4959){ref-type="table-fn"}    2.21±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn4-mmr-13-06-4959){ref-type="table-fn"}    \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}
  Loss in POVD at D28 (mm)                  1.66±0.03              0.72±0.05[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}    0.88±0.10[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn3-mmr-13-06-4959){ref-type="table-fn"}    0.68±0.05[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn4-mmr-13-06-4959){ref-type="table-fn"}    \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}
  Percentage change of POVD at day 28 (%)   57.77±0.79             24.83±1.61[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}   30.42±3.28[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn3-mmr-13-06-4959){ref-type="table-fn"}   23.62±1.40[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn4-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}
  Lumenal area (mm^2^)                      2.60±0.56              4.62±0.27[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}    4.04±0.44[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn3-mmr-13-06-4959){ref-type="table-fn"}    4.54±0.17[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn4-mmr-13-06-4959){ref-type="table-fn"}    \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}
  Neointimal area (mm^2^)                   0.36±0.04              0.12±0.02[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}    0.15±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn3-mmr-13-06-4959){ref-type="table-fn"}    0.13±0.02[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}                                                   \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}
  Medial area (mm^2^)                       0.53±0.04              0.45±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}    0.49±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}                                                   0.47±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}                                                   \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}
  Neointimal/medial                         0.67±0.06              0.26±0.04[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}    0.32±0.06[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn3-mmr-13-06-4959){ref-type="table-fn"}    0.27±0.03[a](#tfn2-mmr-13-06-4959){ref-type="table-fn"}                                                   \<**0.001**[d](#tfn5-mmr-13-06-4959){ref-type="table-fn"}

Data are presented as the mean ± standard deviation and tested by analysis of variance with Tukey\'s test or Dunnet\'s T3 test for post hoc analysis. Bold values indicate a statistically significant difference.

P\<0.05 compared with the control group.

P\<0.05 compared with the CsA group.

P\<0.05 compared with the low-dose group.

P\<0.05 between the 4 groups. VD, vessel diameter; POVD, post-operative vessel diameter.

###### 

Post-operative protein expression of PCNA, VEGF, CDK2 and p21^Cip1^ (optical density) in 24 rabbits.

  Protein     Vehicle control (n=6)   CsA (n=6)                                                   Low-dose tripterygium glycosides (n=6)                                                                     High-dose tripterygium glycosides (n=6)                                                                    P-value
  ----------- ----------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  PCNA        0.091±0.007             0.032±0.005[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"}   0.057±0.009[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn8-mmr-13-06-4959){ref-type="table-fn"}   0.031±0.010[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn9-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[d](#tfn10-mmr-13-06-4959){ref-type="table-fn"}
  VEGF        0.044±0.005             0.010±0.003[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"}   0.030±0.004[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn8-mmr-13-06-4959){ref-type="table-fn"}   0.010±0.002[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn9-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[d](#tfn10-mmr-13-06-4959){ref-type="table-fn"}
  CDK2        0.069±0.003             0.032±0.001[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"}   0.041±0.002[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn8-mmr-13-06-4959){ref-type="table-fn"}   0.030±0.001[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn9-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[d](#tfn10-mmr-13-06-4959){ref-type="table-fn"}
  p21^Cip1^   0.020±0.004             0.087±0.005[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"}   0.049±0.005[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[b](#tfn8-mmr-13-06-4959){ref-type="table-fn"}   0.082±0.010[a](#tfn7-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn9-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[d](#tfn10-mmr-13-06-4959){ref-type="table-fn"}

Data are presented as the mean ± standard deviation and tested by analysis of variance with Tukey\'s test or Dunnet\'s T3 test for post hoc analysis. Bold values indicate a statistically significant difference.

P\<0.05 compared with the control group.

P\<0.05 compared with the CsA group.

P\<0.05 compared with the low-dose group.

P\<0.05 between the 4 groups. PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor; CDK2, cyclin-dependent kinase 2; p21^Cip1^, cyclin-dependent kinase 1.

###### 

Baseline characteristics in 120 patients by group.

  Characteristic          Control (n=40)   Low-dose tripterygium glycosides (n=40)   High-dose tripterygium glycosides (n=40)   P-value
  ----------------------- ---------------- ----------------------------------------- ------------------------------------------ ---------
  Age (years)             64.8±15.8        65.1±16.6                                 63.9±17.2                                  0.945
  Male gender, n (%)      29 (72.5)        31 (77.5)                                 30 (75.0)                                  0.964
  Course (months)         4.9±2.9          4.8±3.2                                   4.9±3.1                                    0.986
  Hypertension, n (%)     28 (70.0)        29 (72.5)                                 30 (75.0)                                  0.966
  CAD, n (%)              20 (50.0)        19 (47.5)                                 21 (52.5)                                  0.973
  CVD, n (%)              10 (25.0)        9 (22.5)                                  11 (27.5)                                  0.964
  Diabetes, n (%)         9 (22.5)         10 (25.0)                                 10 (25.0)                                  0.999
  Hyperlipidemia, n (%)   28 (70.0)        27 (67.5)                                 29 (72.5)                                  0.968
  IMC, n (%)              24 (60.0)        25 (62.5)                                 26 (65.0)                                  0.971
  Leg pain, n (%)         18 (45.0)        16 (40.0)                                 19 (47.5)                                  0.848
  Leg ulcer, n (%)        7 (17.5)         9 (22.5)                                  8 (20.0)                                   0.958
  Leg coldness, n (%)     29 (72.5)        30 (75.0)                                 31 (77.5)                                  0.999
  TASC stage, n (%)                                                                                                             0.945
   A                      19 (47.5)        18 (45.0)                                 20 (50.0)                                  
   B                      18 (45.0)        17 (42.5)                                 17 (42.5)                                  
   C                      3 (7.5)          5 (12.5)                                  3 (7.5)                                    

Age is presented as the mean ± standard deviation and other values are expressed as n (%). Analysis of variance followed by Tukey\'s test for post hoc tests and χ^2^ were implemented. CAD, cardiovascular disease; CVD, cerebrovascular disease; IMC, intermittent claudication; TASC, Trans-Atlantic Inter-Society Consensus.

###### 

IL-10, IL-18, CRP and IMT of lower limbs in 120 patients.

  Parameter                                                            Control (n=40)                                                                                               Low-dose tripterygium glycosides (n=36)                                                                      High-dose tripterygium glycosides (n=32)                                                                     P-value
  -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------
  IL-10 (pg/ml)                                                                                                                                                                                                                                                                                                                                                                                               \<**0.001**[a](#tfn13-mmr-13-06-4959){ref-type="table-fn"}
   Baseline                                                            20.03±7.68                                                                                                   20.87±8.12                                                                                                   20.55±7.67                                                                                                   0.889
   1 month                                                             33.64±9.65[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}                                                    24.21±7.04[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"}    22.58±5.99[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"}    \<**0.001**[a](#tfn13-mmr-13-06-4959){ref-type="table-fn"}
   2 months                                                            30.28±8.68[d](#tfn16-mmr-13-06-4959){ref-type="table-fn"},[e](#tfn17-mmr-13-06-4959){ref-type="table-fn"}    22.38±6.45[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}--[d](#tfn16-mmr-13-06-4959){ref-type="table-fn"}   21.24±5.90[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"},[d](#tfn16-mmr-13-06-4959){ref-type="table-fn"}    \<**0.001**[a](#tfn13-mmr-13-06-4959){ref-type="table-fn"}
   P~time~^\*^~group~[e](#tfn17-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**                                                                                                                                                                                                                                                                                                                            
  IL-18 (pg/ml)                                                                                                                                                                                                                                                                                                                                                                                               \<0.001[a](#tfn13-mmr-13-06-4959){ref-type="table-fn"}
   Baseline                                                            42.70±11.67                                                                                                  41.91±11.85                                                                                                  41.79±11.97                                                                                                  0.932
   1 month                                                             68.97±15.13[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}                                                   46.71±13.21[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"},[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"}   42.94±12.06[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"}                                                   \<**0.001**[a](#tfn13-mmr-13-06-4959){ref-type="table-fn"}
   2 months                                                            55.64±13.41[d](#tfn16-mmr-13-06-4959){ref-type="table-fn"},[e](#tfn17-mmr-13-06-4959){ref-type="table-fn"}   42.70±12.62[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"}                                                   41.14±11.75[c](#tfn15-mmr-13-06-4959){ref-type="table-fn"},[d](#tfn16-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[a](#tfn13-mmr-13-06-4959){ref-type="table-fn"}
   P~time~^\*^~group~[e](#tfn17-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**                                                                                                                                                                                                                                                                                                                            
  CRP                                                                                                                                                                                                                                                                                                                                                                                                         0.311
   Baseline                                                            1.08±0.22                                                                                                    1.09±0.22                                                                                                    1.11±0.24                                                                                                    
   1 month                                                             1.19±0.18[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}                                                     1.09±0.19                                                                                                    1.08±0.15                                                                                                    
   2 months                                                            1.19±0.23[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}                                                     1.08±0.15                                                                                                    1.12±0.23                                                                                                    
   P~time~^\*^~group~[e](#tfn17-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**                                                                                                                                                                                                                                                                                                                            
  IMT of lower limb (mm)                                                                                                                                                                                                                                                                                                                                                                                      0.277
   Baseline                                                            1.08±0.22                                                                                                    1.09±0.22                                                                                                    1.11±0.24                                                                                                    
   1 month                                                             1.19±0.18[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}                                                     1.09±0.19                                                                                                    1.08±0.15                                                                                                    
   2 months                                                            1.19±0.23[b](#tfn14-mmr-13-06-4959){ref-type="table-fn"}                                                     1.08±0.15                                                                                                    1.09±0.22                                                                                                    
   P~time~^\*^~group~[e](#tfn17-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**                                                                                                                                                                                                                                                                                                                            

Data are presented as the mean ± standard deviation and tested by generalized estimation equation, Bonfferoni\'s correction test was applied for multiple comparisons. Bold values indicate statistically significant results.

P\<0.05 between the three groups.

P\<0.05, compared with baseline.

P\<0.05 compared with the control group.

P\<0.05 compared with the previous 1 month.

P value of an interaction term consisting of time and group. Once a significant result of the interaction term is revealed (P~time~^\*^~group~^g^ \<0.05), the time effect on a given variable should be separately tested by group. IL, interleukin; CRP, C-reactive reactive protein; IMT, intima-media thickness.

###### 

Stent patency rates and ABI in 120 patients.

  Parameter                           Vehicle control (n=40)   Low-dose tripterygium glycosides (n=33)                    High-dose tripterygium glycosides (n=32)                   P-value
  ----------------------------------- ------------------------ ---------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------
  Number of unobstructed stents (%)                                                                                                                                                  
   6 Months                           27 (67.5)                30 (90.9)[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   30 (93.8)[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   **0.004**[b](#tfn20-mmr-13-06-4959){ref-type="table-fn"}
   12 Months                          25 (62.5)                28 (84.8)[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   29 (90.6)[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   **0.009**[b](#tfn20-mmr-13-06-4959){ref-type="table-fn"}
  ABI                                                                                                                                                                                
   6 Months                           0.47±0.23                0.73±0.17[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   0.79±0.16[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[b](#tfn20-mmr-13-06-4959){ref-type="table-fn"}
   12 Months                          0.49±0.18                0.70±0.22[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   0.75±0.19[a](#tfn19-mmr-13-06-4959){ref-type="table-fn"}   \<**0.001**[b](#tfn20-mmr-13-06-4959){ref-type="table-fn"}

Number of stents without obstruction is presented as count (%) and tested by χ^2^ test. ABI is shown as the mean ± standard deviation and tested by analysis of variance, followed by post hoc testing using Tukey\'s test. Bold values indicate a statistically significant difference.

P\<0.05, compared with the control group.

P\<0.05 between the 3 groups. ABI, ankle-brachial index.
